Form 8-K - Current report:
SEC Accession No. 0000950170-24-073998
Filing Date
2024-06-17
Accepted
2024-06-17 07:10:10
Documents
13
Period of Report
2024-06-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ovid-20240617.htm   iXBRL 8-K 40143
2 EX-99.1 ovid-ex99_1.htm EX-99.1 45853
3 GRAPHIC img34400995_0.jpg GRAPHIC 29211
  Complete submission text file 0000950170-24-073998.txt   248341

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ovid-20240617.xsd EX-101.SCH 24851
16 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20240617_htm.xml XML 4705
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 241046936
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)